Clinical Trial Update: Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 study ATI-1777 in patients aged 12-65 with mild to severe atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• ATI-1777

Snippet

Sponsor: Aclaris Therapeutics, Inc. | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED